π Entity
Durvalumab
Pharmaceutical drug
π Rating
1 news mentions Β· π 0 likes Β· π 0 dislikes
π Topics
- Pharmaceutical Approval (1)
- Oncology (1)
π·οΈ Keywords
AstraZeneca (1) Β· Imfinzi (1) Β· EU approval (1) Β· gastric cancer (1) Β· early-stage cancer (1) Β· oncology (1) Β· regulatory (1) Β· treatment (1)
π Key Information
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1ΞΊ) monoclonal antibody that binds to programmed cell death ligand 1 (PD-L1) on cancer cells and blocks interactions with PD-1 and CD80 (B7.1) on T cells.
π° Related News (1)
π Entity Intersection Graph
People and organizations frequently mentioned alongside Durvalumab:
-
AstraZeneca Β· 1 shared articles